PozzilliPBattelinoTDanneTHovorkaRJarosz-ChobotPRenardE. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016;32(1):21-39. doi:10.1002/dmrr.2653.
2.
GianiE. Impact of new technologies on diabetes care. World J Diabetes. 2015;6(8):999-1004. doi:10.4239/wjd.v6.i8.999.
3.
MinicucciWJ. Uso de bomba de infusão subcutânea de insulina e suas indicações. Arq Bras Endocrinol Metabol. 2008;52(2):340-348. doi:10.1590/s0004-27302008000200022.
4.
MurataT. Safety of the batteries and power units used in insulin pumps: a pilot cross-sectional study by the association for the study of innovative diabetes treatment in Japan. J. Diabetes Investig. 2018;9(4):903-907. doi:10.1111/jdi.12765.
5.
RossPLMilburnJReithDMWiltshireEWheelerBJ. Clinical review: insulin pump-associated adverse events in adults and children. Acta Diabetol. 2015;52(6):1017-1024. doi:10.1007/s00592-015-0784-2.
6.
NevesALDMartinsLEGGabbayMALCavicchioliGTenorioFSCunhaTS. Insulin pump-associated adverse events in a Brazilian reference center for the treatment of diabetes mellitus: proposal for a taxonomy of device failures in adults, adolescents, and children. J Diabetes Sci Technol. 2024;18(1):74-81 doi:10.1177/19322968221106196.
